Core Insights - The AI healthcare sector is experiencing significant stock performance, with JingTai Holdings (02228.HK) seeing a notable increase in share price, reaching a new high of HKD 12.57 per share, up 5.63% on September 25, and a year-to-date increase of 107.02% [1] Group 1: Company Developments - JingTai Holdings signed a cooperation letter of intent with Baicheng Pharmaceutical (301096.SZ) to utilize its "AI + Robotics" platform for new drug development, focusing on unmet clinical needs in various disease areas [1] - The collaboration aims to advance the development and incubation of innovative drug pipelines and explore broader commercial cooperation, including the potential establishment of a joint venture [1] - JingTai Holdings has achieved a significant milestone in clinical research with the new PRMT5 inhibitor PEP08, receiving approvals for clinical trials in Australia and Taiwan, confirming milestone payments for the project [2] Group 2: Market Position and Future Prospects - The company is included in the FTSE China Small Cap Index as of September 19, indicating its growing market presence [2] - According to招商证券, JingTai Holdings' AI pharmaceutical business is progressing steadily, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [3] - The company has secured a pipeline cooperation agreement with DoveTree worth USD 5.99 billion, receiving an initial payment of USD 51 million, contributing positively to its performance [3] - JingTai Holdings is also exploring cross-industry applications of its technology platform, including new materials, which may expand its market potential [3]
牵手百诚医药推进AI新药研发合作，晶泰控股今年以来股价翻番